The relative binding of acetaminophen, lidocaine, phenobarbital, phenyloin, quinidine, and theophylline to human tissues in vitro was studied using equilibrium dialysis. Pooled human serum plus homogenates of brain, heart, liver, and placenta were incubated at 4~ with each drug at concentrations of 5 and 10 mmol/L. The percent binding of each drug to each tissue was calculated. Binding of 5 % or less was considered to be negligible. By drug, the following relative binding orders were observed for those tissues demonstrating binding: acetaminophen (heart > brain, serum); lidocaine (no appreciable binding observed); phenobarbital (serum only); phenytoin (heart and liver equally; serum not studied); quinidine (serum > liver > brain, placenta); and theophylline (serum > liver). By matrix, serum bound all drugs studied except for lidocaine. Liver bound only phenytoin, quinidine, and theophylline; heart bound only acetaminophen and phenytoin; brain bound only acetaminophen and quinidine; and placenta bound only quinidine.
Introduction
Although the literature is replete with information regarding the binding of therapeutic drugs to tissues, most comprehensive studies have focused on animals (1, 2) . Furthermore, the data available on binding of drugs in man have largely been limited to binding in serum (3) (4) (5) . Few, if any, studies have compared the relative binding of a series of therapeutic drugs with the same human tissues simultaneously and under identical conditions. This study was designed to investigate the relative binding of acetaminophen, lidocaine, phenobarbital, phenytoin, quinidine, and theophylline to human brain, heart, liver, placenta, and serum.
Experimental

Human Tissues
Pooled human serum (catalog #82-320) was purchased from ICN Biomedicals (Aurora, OH). The total protein concentration was 73 g/L, and the albumin concentration was 43 g/L.
Placenta was obtained 12 h after a normal full-term vaginal delivery by a 28-year-old woman. Brain, heart, and liver were acquired from a 35-year-old man who had died instantly 20 h earlier after having been hit by an automobile. Neither individual was known to have a history of drug use or disease.
Homogenization of tissues
Immediately upon receipt, solid tissues were homogenized at 4~ in a Waring blender (Scientific Products Division, Baxter Diagnostics, McGaw Park, IL) with phosphate buffer (0.1 rnol/L, pH 7.4) containing 25 mL of saturated sodium fluoride per liter. For each gram of tissue wet weight, 10 mL of buffer was used. The resulting whole homogenate was strained through a colander and frozen (-20~ until use. Sodium fluoride has been shown to inhibit enzymatic activity in tissues, thereby retarding degradation of drugs (6). Aliquots of serum and each tissue homogenate were submitted to analysis for each drug to be studied, and these analyses revealed that each sample was, in fact, negative for that drug.
Drugs
Acetaminophen ( (Matheson Coleman & Bell) were each prepared at concentrations of 5 and 10 mmol/L in phosphate buffer, 0.1 tool/L, pH 7.4 (containing 25 mL of saturated sodium fluoride per liter) in each of the human tissue homogenates and pooled human serum. When necessary, alkalinization or acidification of the solution was performed to achieve solubility. ecause of solubility problems, phenytoin was not studied in serum; however, it was soluble in the aqueous tissue homogenates.
Equilibrium dialysis
Equilibrium dialysis was performed using dialysis chambers (Bel-Art #D-1609-5), 5 mL on each side of the membrane. Dialysis membranes (Bel-Art #H-40299; 0.073-ram thickness; molecular-weight cutoff, 6000) were purchased from Scientific Products Division, Baxter Diagnostics.
To enhance the establishment of equilibrium, each drug in the respective homogenate was dialyzed against the same drug concentration (5 and 10 mmol/L) in phosphate buffer for 17-20 h on a platform rocker in a walk-in refrigerator at 4~ Each experiment was performed in duplicate for each drug, each tissue, and each drug concentration. The dialysis time was previously shown to be sufficient for the establishment of equilibrium in other studies in this laboratory (7). The temperature of 4~ was used in order to decrease the potential for bacterial or fungal growth or both, which could conceivably disrupt binding. (Bacteriostatic agents were not added because these could potentially disrupt binding.) The lower temperature used (4~ has also been shown to enhance preservation of some drugs (6).
Drug analysis
Following dialysis, each homogenate and buffer solution was removed and was diluted in pooled human plasma (confirmed as drug-free for each drug studied) in order to achieve therapeutic concentrations suitable for conventional plasma measurements and to dilute homogenates to preclude matrix effects in the analyses. The following dilutions were used: acetaminophen, x 50; lidocaine, • 500; phenobarbital, • 100; phenytoin, • 100; quinidine, • 1000; and theophylline, x 100.
Total-drug concentrations were measured by commercial enzyme immunoassays designed for plasma samples ( 
Calculation of binding
Binding was expressed as the percent of drug bound. The concentration of drug in the binder (homogenate or serum) side of the dialysis chamber represented total [bound (B) + free (F)] drug, whereas that in the buffer side represented free (F) drug alone. The concentration of bound drug (B) was calculated by subtraction of the drug concentration in the buffer from that in the binder. The resulting concentration (B) was divided by the concentration in the binder (B + F) and expressed as percent of drug bound (%B). This is summarized in the following formula:
where C is the drug concentration.
Results
Binding data, including concentrations of total drug (binder) (B + F), free drug (buffer) (F), and bound drug (B); the ratio (B/F); and the percent of drug bound (%B) are expressed for each drug in Tables I-VI. Each result is the composite of two experiments. Values for each experiment generally agreed within 15% of each other. Binding was noted for each drug except lidocaine, which, in all tissues studied, showed negligible binding of 5% or less (Table II) .
Discussion
The present investigation attempted to determine the relative binding of six widely used therapeutic agents by studying them simultaneously under identical conditions in the same tissues. It was not the purpose of this study to identify specific tissue binders; hence, whole (unsectioned) tissue was used in this study.
Although many, if not most, binding studies are performed at 37~ this study was done at 4~ in order to inhibit degradation of the drugs (6) and to reduce the possibility of bacterial or fungal growth or both during prolonged incubation. It is known that, at least for some drugs (e.g., chlorpromazine) (1), binding is reduced at lower temperatures. Sodium fluoride was added in attempt to enhance preservation of the drugs studied, and it is conceivable that this agent could have altered binding. Homogenization and freezing of tissue could also have disrupted the binding sites. Although the decedent from whom brain, heart, and liver were obtained and the woman from whom placenta was obtained were not known to have disease, it is theoretically possible that binding demonstrated by these tissues from single individuals may not be representative of the entire population. Finally, it is inevitable that some autolysis of tissue occurred during the period of tissue preparation, and this, too, could have potentially altered the binding sites. Nonetheless, with the exception of lidocaine, more than 5% binding to at least some tissues was noted for each drug studied under these conditions. Furthermore, all tissues studied bound (> 5%) at B/F ~ least some of the drugs. This protocol has been successfully used in the study of other NB NB drugs by this laboratory (7). NB NB Drug concentrations of 5 and 10 mmol/L NB NB (greatly in excess of therapeutic plasma con-NB NB centrations) were used in order to maxi-NB NB mize the potential for binding and to permit NB NB subsequent plasma dilution of any tissue matrix effect in the drug assay. NB NB Serum bound all drugs studied in this NB NB series except for lidocaine (phenytoin not 0.24 20 studied with serum). The percent binding to 0.20 16 serum observed in the present study was Each considerably lower than that of some reports in the literature: acetaminophen, none at 5 retool/L, 12% at 10 mmol/L (versus 25%) (4); iidocaine, no appreciable binding at 5 and 10 mmol/L (versus 70%) (3, 5) ; phenobarbital, 20% at 5 mmol/L, 16% at 10 mmol/L (versus 50%) (3-5); phenytoin, not studied; quinidine, 36% at
5 mmol/L, 29% at 10 mmol/L (versus 75%) NB NB (4, 5) ; and theophylline, 29% at 5 mmol/L, 0.04 4 19% at 10 mmol/L (versus 55%) (3, 4) . This may have been a result of the lower tern-0.10 9 perature used or of the other variables pre- 5 mmol/L, 29% at 10 mmol/L; liver, 21% at 5 mmol/L) ( Table V) ; and theophylline (serum, 29% at 5 retool/L) (Table VI) . Throughout the series, generally good agreement was noted between the percent drug bound at 5 and 10 mmol/L drug concentrations, except for theophylline (serum: 29% at 5 retool/L, 19% at 10 mmol/L) and acetaminophen (serum: no binding at 5 mmol/L, 12% at 10 mmol/L). For the latter, however, binding is known to decrease substantially at lower concentrations (3, 5) .
Knowledge of relative tissue binding may contribute to a better understanding of the target organ activity and pharmacokinetic profiles of the six drugs in man. because of drug solubility problem); quinidine (serum > liver > brain, placenta); and theophylline (serum > liver) (Tables  I-VI) . Binding of 5% or less was arbitrarily disregarded as negligible and may have been due to nonspecific binding to tissue lipids.
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